-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation- - Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21- GENEVA ...
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug ...
Jun. 10, 2021 1:43 AM ETObsEva SA (OBSEF) Stock OBSEFBy: SA News Team ...
The 34th annual conference of All India Coordination Committee (AICC) Royal College of Obstetricians and Gynaecologists (RCOG) 2021 began on Friday. In a message, Kerala Chief Minister Pinarayi ...
GENEVA, Switzerland and BOSTON, MA – June 10, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive ...
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA – June 2, 2021 – ...
GENEVA, Switzerland and BOSTON, MA – June 10, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive ...
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA - June 2, 2021 - ...
GENEVA, Switzerland and BOSTON, MA - June 10, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive ...
- Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21- “These positive data play a critical role in our development plans for ebopiprant, and we are excited to build on this momentum,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback